WSR 12-21-099



[ Filed October 23, 2012, 9:53 a.m. ]

Notice of Interpretive or Policy Statement

     In accordance with RCW 34.05.230(12), following is a list of policy and interpretive statements issued by the health care authority (HCA).


Legal and Administrative Services

     Document Title: Provider Notice #12-88.

     Subject: Medicaid program of the HCA is publishing a revised Prescription Drug Program Medicaid Provider Guide.

     Effective for dates of service on and after November 1, 2012, the medicaid program of the HCA is implementing outpatient hemophilia treatment requirements in accordance with WAC 182-531-1625. The HCA will no longer pay for hemophilia- and von Willebrand-related products when dispensed by a retail or specialty pharmacy. The HCA will pay for hemophilia- and von Willebrand-related products shipped to fee-for-service clients only when the products are dispensed through a qualified hemophilia center of excellence. Clients may continue to receive their hemophilia treatment and care through their current prescriber. Clients are not required to change their primary care relationship or their current prescriber of hemophilia- and von Willebrand-related products.

     For additional information, contact Amber Lougheed, HCA, P.O. Box 45504, phone (360) 725-1349, TDD/TTY 1-800-848-5429, fax (360) 586-9727, e-mail, web site